[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2152865A1 - Use of bisphosphonates in pharmaceutical preparations intended for intramuscular use - Google Patents

Use of bisphosphonates in pharmaceutical preparations intended for intramuscular use

Info

Publication number
ES2152865A1
ES2152865A1 ES009802412A ES9802412A ES2152865A1 ES 2152865 A1 ES2152865 A1 ES 2152865A1 ES 009802412 A ES009802412 A ES 009802412A ES 9802412 A ES9802412 A ES 9802412A ES 2152865 A1 ES2152865 A1 ES 2152865A1
Authority
ES
Spain
Prior art keywords
acid
bisphosphonates
pharmaceutical preparations
intramuscular
preparations intended
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES009802412A
Other languages
Spanish (es)
Other versions
ES2152865B1 (en
Inventor
Tiberio Bruzzesse
Angelo Bonabello
Giovanni Mozzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prodotti Antibiotici SpA
Original Assignee
Prodotti Antibiotici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prodotti Antibiotici SpA filed Critical Prodotti Antibiotici SpA
Publication of ES2152865A1 publication Critical patent/ES2152865A1/en
Application granted granted Critical
Publication of ES2152865B1 publication Critical patent/ES2152865B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Pharmaceutical preparations containing a bisphosphonate and benzyl alcohol have been found to overcome the pain and discomfort associated with preparations containing bisphosphonates only when administered by intramuscular injection. The bisphosphonates may comprise alendronic acid, clodronic acid, etiodronic acid, medronic acid or pamidronic acid, or pharmaceutically acceptable salts thereof. These preparations may be used for the treatment of skeletal and bone disorders such as pagets disease and osteoporosis. Tests were performed on rabbits.
ES9802412A 1997-11-21 1998-11-17 USE OF BISPHOSPHONATES IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR INTRAMUSCULAR USE. Expired - Fee Related ES2152865B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002603 IT1296495B1 (en) 1997-11-21 1997-11-21 USE OF BISPHOSPHONATES IN THE PREPARATION OF PHARMACEUTICAL FORMS FOR INTRAMUSCULAR ADMINISTRATION

Publications (2)

Publication Number Publication Date
ES2152865A1 true ES2152865A1 (en) 2001-02-01
ES2152865B1 ES2152865B1 (en) 2001-08-16

Family

ID=11378254

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9802412A Expired - Fee Related ES2152865B1 (en) 1997-11-21 1998-11-17 USE OF BISPHOSPHONATES IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR INTRAMUSCULAR USE.

Country Status (6)

Country Link
BE (1) BE1012137A3 (en)
DE (1) DE19853483A1 (en)
ES (1) ES2152865B1 (en)
FR (1) FR2771638B1 (en)
GB (1) GB2331459A (en)
IT (1) IT1296495B1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1136069A1 (en) * 2000-03-21 2001-09-26 SPA SOCIETA' PRODOTTI ANTIBIOTICI S.p.A. Pharmaceutical compositions containing clodronates for high local tolerance intramuscular administration
ES2394211T3 (en) * 2000-06-20 2013-01-23 Novartis Ag Administration procedure of bisphosphonates
DK1591122T3 (en) * 2000-06-20 2013-02-25 Novartis Ag Process for administration of bisphosphonates
US6548042B2 (en) 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
ITTO20020406A1 (en) * 2002-05-13 2003-11-13 Chiesi Farma Spa FORMULATIONS OF BISPHOSPHONATES FOR INJECTABLE USE.
AU2004226323A1 (en) * 2003-03-26 2004-10-14 Becton, Dickinson And Company Use of benzyl alcohol, and other phenolic preservatives to reduce pain during intradermal injection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03190823A (en) * 1989-12-21 1991-08-20 Snow Brand Milk Prod Co Ltd Erythropoietin hypodermic or intramuscular administration agent
EP0449405A2 (en) * 1990-01-31 1991-10-02 Merck & Co. Inc. Use of bisphosphonic acids for the treatment of calcium metabolism disorders
WO1995011029A1 (en) * 1993-10-19 1995-04-27 Merck & Co., Inc. Combination of bisphosphonates and growth hormone secretagogues
WO1995028936A1 (en) * 1994-04-21 1995-11-02 Merck & Co., Inc. Use of bisphophonates for inhibiting bone resorption following implantation of orthopedic prosthesis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0051163A3 (en) * 1980-11-03 1983-02-16 Dr. Franz Köhler Chemie KG A 4-dimethylaminophenol-hydrochloride solution for painless intramuscular administration, and process for its preparation
JPS5862652A (en) * 1981-10-08 1983-04-14 Konishiroku Photo Ind Co Ltd Formation of direct positive color image

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03190823A (en) * 1989-12-21 1991-08-20 Snow Brand Milk Prod Co Ltd Erythropoietin hypodermic or intramuscular administration agent
EP0449405A2 (en) * 1990-01-31 1991-10-02 Merck & Co. Inc. Use of bisphosphonic acids for the treatment of calcium metabolism disorders
WO1995011029A1 (en) * 1993-10-19 1995-04-27 Merck & Co., Inc. Combination of bisphosphonates and growth hormone secretagogues
WO1995028936A1 (en) * 1994-04-21 1995-11-02 Merck & Co., Inc. Use of bisphophonates for inhibiting bone resorption following implantation of orthopedic prosthesis

Also Published As

Publication number Publication date
ITMI972603A1 (en) 1999-05-21
GB9825409D0 (en) 1999-01-13
DE19853483A1 (en) 1999-05-27
GB2331459A (en) 1999-05-26
IT1296495B1 (en) 1999-06-25
ES2152865B1 (en) 2001-08-16
BE1012137A3 (en) 2000-05-02
FR2771638A1 (en) 1999-06-04
FR2771638B1 (en) 2000-09-08
GB2331459A8 (en) 1999-07-15

Similar Documents

Publication Publication Date Title
ES2190244T3 (en) USE OF THE PARTIROID HORMONE CONSTITUTED BY A SEQUENCE OF AMINO ACIDS 1-34 OF THE HUMAN PARTIROID HORMONE TO REDUCE THE RISK OF VERTEBRAL AND NON-VERTEBRAL BONE FRACTURES.
IL155363A0 (en) Use of bisphosphonates for pain treatment
BR0107755A (en) Parenteral composition, process for preparing and using this composition, process for the treatment and prevention of diseases that involve bone resorption and a device for sustained local and systemic release
BR9510168A (en) Polyamino acid compound composition unit dosage form and method for preparing a composition
EP0552256A4 (en)
DK0833643T3 (en) Formulations of anhydrous monosodium salt of alendronate and their use in the treatment of bone disorders
NO964567D0 (en) Wet granulation formulation for bisphosphonic acids
BR0010808A (en) Pharmaceutical compositions and uses
SE9702401D0 (en) Pharmaceutical use
WO2001089494A3 (en) Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
ES2152865A1 (en) Use of bisphosphonates in pharmaceutical preparations intended for intramuscular use
EA200100080A1 (en) DRUGS CONTAINING BISPHOSPHONE ACIDS AND THEIR DERIVATIVES INTENDED FOR PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES AND ALLERGIES
IL141218A0 (en) Alendronic acid, pharmaceutically acceptable salts thereof or mixtures thereof, for use as a medicament or for use in the manufacture of a medicament, pharmaceutical compositions and kits comprising any of thereof, all for inhibiting bone resorption

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20010201

Kind code of ref document: A1

Effective date: 20010201

PC2A Transfer of patent
FD2A Announcement of lapse in spain

Effective date: 20110816